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Abstract 
 
The general consensus amongst sport and exercise genetics researchers is that genetic tests based on 
current knowledge have little or no role to play in talent identification or the individualised 
prescription of training to maximise performance or minimise injury risk.  Despite this, genetic tests 
related to sport and exercise are widely available on a commercial basis.  This study assessed 
commercially-available genetic tests related to sport and exercise currently marketed via the internet.  
Twenty-two companies were identified as providing direct-to-consumer (DTC) genetic tests marketed 
in relation to human sport or exercise performance or injury.  The most commonly-tested variant was 
the R577X SNP in the ACTN3 gene, tested by 85% of the 13 companies that appear to present 
information about their genetic tests on websites - which corresponds with our assessment that 
ACTN3 R577X is currently the polymorphism with the strongest scientific evidence in support of an 
association with sport and exercise phenotypes.  54% of companies that present information about 
their genetic tests used panels of 2-21 variants, including several with very limited supporting 
scientific evidence.  46% of companies tested just a single variant, with very low ability to explain 
complex sport and exercise phenotypes.  It is particularly disappointing that 41% of companies 
offering DTC genetic tests related to exercise and sport did not appear to state publicly the genetic 
variants they assess, making scrutiny by academic scholars and consumers impossible.  Companies 
offering DTC genetic tests related to sport and exercise should ensure that they are responsible in their 
activities. 
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Introduction 
 
Traditional sport and exercise science research, conducted primarily over the last ~40 years but with a 
considerably earlier history, has arguably been conducted at a descriptive physiological level.  
Interventions such as particular training regimens or specific nutritional strategies have nevertheless 
been applied effectively to improve sports performance, as well as provide public health lifestyle 
recommendations.  However, the underlying physiological mechanisms have remained largely 
unknown.  Recently, sport and exercise science has entered a new era, moving from a descriptive to 
mechanistic paradigm, examining the genomic basis of interindividual variability in performance and 
the intracellular signalling pathways that explain the effects of training and nutritional interventions.  
This new era of sport and exercise science has been called ‘molecular exercise physiology’ (Spurway 
and Wackerhage 2006). 
 
Twin and family studies performed by pioneers such as Bouchard in North America and by 
Klissouras, Komi and others in Europe have shown that many exercise-related traits are partly 
inherited.  These traits include anaerobic power, the maximal rate of oxygen uptake, maximal running 
speed, muscle enzyme activity, muscle fibre type composition and the trainability of several of these 
(Bouchard et al. 1997). The heritability (the proportion of phenotypic variation in a population which 
is due to inter-individual genetic variation) may be as high as 50% for maximal oxygen uptake 
(VO2max) (Bouchard et al. 1998) and its trainability (Bouchard et al. 1999). Several other exercise 
related phenotypes such as skeletal muscle fibre type composition (Simoneau and Bouchard 1995), 
muscle enzyme activities (Bouchard et al. 1986) and leg strength (Zhai et al. 2005) also have 
estimated heritability values congregating around the 50% value, with some phenotypes above this 
typical 50% estimated heritability such as mesomorphy at around 80% (Peeters et al. 2007).  
However, comparatively little is known about the molecular variations in the DNA sequence that add 
up to the often 50% or more estimated heritability for major sport- and exercise-related traits.  
Consequently, in an effort to take genetic research from the classical indirect approach to an era that 
uses a molecular genetics approach, identifying the specific DNA sequence variations that contribute 
to the observed heritability has become an increasing focus of research in recent years.  The genetic 
contribution to elite athlete status directly (i.e. not simply implied via associations with isolated 
physiological characteristics) has been estimated at a value approaching 70% (de Moor et al. 2007) 
and, as documented in a recent review article (Ahmetov and Fedotovskaya 2012), there has been 
notable growth in the number of published research articles on the genomics of elite athlete status 
(Figure 1). 
 
<<< Figure 1 near here >>> 
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Increasingly advanced genomic tools are now used to investigate the genetic limitations to human 
exercise performance, and the growing body of knowledge is perhaps beginning to approach that 
required for application to select talented athletes for intensive training, individualise training 
regimens to improve performance and modulate training load to minimize injury risk.  However, there 
is a requirement for greater replication of the >250 genotype-phenotype associations reported to date 
(Ahmetov and Fedotovskaya 2012; Bray et al. 2009; Hughes et al. 2011).  Selected examples of 
promising but still rather controversial associations between genetic variants and aspects of exercise 
performance include an insertion/deletion (I/D) polymorphism in the angiotensin I converting enzyme 
(peptidyl dipeptidase A) 1 (ACE) gene associated with the training-responsiveness of oxygen uptake 
during exercise (Williams et al. 2000), a single nucleotide polymorphism (SNP) in the actinin, alpha 3 
(ACTN3) gene associated with sprint performance (Ahmetov et al. 2011; Yang et al. 2003) and a SNP 
in the hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) (HIF1A) 
gene associated with endurance performance (Doring et al. 2010). 
 
The common polymorphisms identified to date only account, individually, for a small proportion of 
the interindividual variability in phenotype.  To explain a larger proportion of the variability, either 
rare variants of large effect or favourable combinations of many common variants need to be 
identified.  Evidence regarding rare variants of large effect is currently limited to very few 
documented examples (de la Chapelle et al. 1993; Schuelke et al. 2004).  However, using 6-10 
common variants, elite athletes in certain sports have been shown to differ in polygenic profile from 
non-athletes and from elite athletes in other sports (Ahmetov et al. 2009; Ruiz et al. 2010; Ruiz et al. 
2009) and such differences will become clearer as larger panels of appropriate variants are included.  
It has been estimated that if more than ~15-20 common variants contribute to sporting ability (most 
scientists suspect it is many more) then more genetic potential is present in the human species than is 
ever likely to manifest itself in one individual (Williams and Folland 2008). 
 
Given the rather preliminary nature of the research evidence to date regarding the genetic composition 
of elite athletes and regarding the genetics of training responsiveness, it is noteworthy, and perhaps 
surprising, that several direct-to-consumer (DTC) tests of exercise-related genetic potential are 
available on a commercial basis.  The purpose of this article is to provide a summary of the direct-to-
consumer exercise-related genetic tests currently available in 2013, and to provide some commentary 
on the value of the information that may be gleaned from such tests.  It is not the aim of this article to 
comment on the financial costs of the tests or on the concept of value-for-money. 
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Figure 1. Growth in the number of published articles in relation to sports genomics each year from 
1997 to 2012 (June). From Ahmetov and Fedotovskaya (2012). 
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Method 
 
In June 2013, internet searches were conducted to identify commercially-available sport and exercise-
related genetic tests for humans.  Four English language internet search terms GENETIC, TEST, 
EXERCISE and SPORT were used in a simple search in two popular internet search engines, as a 
potential consumer might do.  In addition, other commercially-available sport and exercise-related 
genetic tests, of which the authors were already aware, were included in the results. 
 
The websites of the commercial operations identified were explored manually and, if available, details 
about the numbers and identities of genetic variants being tested were identified. The recorded 
number of variants tested, and the names of the genes corresponding to the variants tested, required 
some subjective interpretation for their relevance to sport and exercise where this was not clear on the 
websites identified.  For example, genetic tests marketed in relation to body composition phenotypes 
but not clearly marketed as having a direct interaction with exercise were not included. 
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Results 
 
Twenty-two companies were identified as providing DTC genetic tests that were marketed in relation 
to sport or exercise performance or injury.  The companies are listed in Table 1 together with 
summary information about the genetic tests - if found on the websites of those companies. 
 
For 9 of the 22 companies (41%), it was not possible to identify the specific DNA sequence variants 
tested. 
 
For the 13 companies that did present information about their genetic tests on their websites, the most 
commonly-tested variant was the R577X SNP in the ACTN3 gene that was tested by 11 of those 13 
companies (85%). The second most commonly-tested variant was the ACE I/D polymorphism that 
was tested by 6 of those 13 companies (46%). 
 
A single genetic variant was tested by 5 of the 13 companies (46%) that presented information about 
their genetic tests, with the remaining 8 companies testing 2-21 variants. 
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Table 1. Companies found to be providing direct-to-consumer genetic tests marketed as being related 
to sport and exercise performance or sports injury. Data may not be 100% accurate because accuracy 
is dependent on the ability to navigate the websites appropriately, and the contemporary accuracy of 
the information provided on the websites. Gene names are in several instances listed verbatim as 
presented on the company websites, even though some gene names given do not conform to the 
standard nomenclature. 
 
Company Website name Number 
of variants 
tested 
Genes of variants tested 
(according to the websites) 
23andMe 23andme.com 1 ACTN3 
Advanced Health 
Care 
advanceddna.in 1 ACTN3 
Asper Biotech asperbio.com 2 ACE, ACTN3 
Athleticode athleticode.com 1 APOE 
Atlas Sports 
Genetics 
atlasgene.com 1 ACTN3 
Beyond Nutrition beyond-nutrition.co.uk nf nf 
C2DNA c2dna.com nf nf 
Cosmetics DNA cosmetics-dna.com nf nf 
CyGene Direct cygene.infinityarts.com 6 ACE, APOE, BDKRB2, ENOS, VDR 
DNA Fit dnafit.com 20 ACE, ACTN3, ADRB2, AGT, 
BDRKB2, COL1A1, COL5A1, CRP, 
GDF5, IL6, IL-6R, NRF-2, PPARA, 
PPARGC1A, SOD2, TNF, TRHR, 
VDR, VEGF 
DNAlysis dnalysis.co.za 20 ACE, ACTN3, ADRB2, AGT, BDRKB, 
COL1A1, COL5A1, CRP, GDF5, IL6, 
IL-6R, NRF-2, PPARA, PPARGC1A, 
SOD2, TNF, TRHR, VDR, VEGF 
GenEffect geneffect.com 1 ACTN3 
Gene Guiide geneguiide.com nf nf 
Gonidio gonidio.com 21 ACE, ACTN3, ADRA2A, ADRB1, 
ADRB2, AMPD1, BDKRB2, CHRM2, 
CK-MM, COL1A1, COL5A1, DIO1, 
EPOR, HBB, HIF-1, MCT-1, MMP3, 
NOS3, PPARD, PPARg-C1, VEGF 
FamilyTreeDNA familytreedna.com 1 ACTN3 
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Institute for 
Optimum Nutrition 
ion.ac.uk nf nf 
MyGene mygene.com.au nf nf 
Nutragene nutragene.com 3 ACTN3, ADRB2, ADRB3 
Pathway Genomics pathway.com nf nf 
PlayDNA playdna.co.uk nf nf 
Warrior Roots warriorroots.com 9 ACE, ACTN3, ADRB2, DIO1-D1a, 
DIO1-D1b, HIF1, MCT1, NOS3, 
PPARGC1A 
XRGenomics xrgenomics.com nf nf 
 
nf = Information not found 
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Discussion 
 
The genetic variants tested most frequently by the companies providing DTC genetic tests related to 
sport and exercise were polymorphisms in the ACTN3 and ACE genes, which presumably reflects the 
fact that more research work has been conducted on these polymorphisms than any others in the 
context of sport and exercise.  Although the true role of the ACTN3 and ACE variants in skeletal 
muscle metabolism and strength traits remains controversial (Perusse et al. 2013), in a recent meta-
analysis the ACE II genotype was associated with physical performance (odds ratio = 1.23; 95% CI 
1.05-1.45), especially endurance performance (odds ratio 1.35; 95% CI 1.17-1.55), while ACTN3 RR 
genotype was associated with speed and power performance (odds ratio = 1.21; 95% CI 1.03-
1.42)(Ma et al. 2013).  Therefore, despite some uncertainty, one can understand individuals interested 
in exercise and sport wishing to learn about their own genetic composition within these two well-
studied genes - even if those discrete variants only impart a very small proportion of the total genetic 
influence, as is generally accepted (Ahmetov et al. 2011; Hughes et al. 2011; Pitsiladis et al. 2013; 
Williams and Folland 2008).  So the provision of a service for the testing of the ACTN3 R577X and 
ACE I/D polymorphisms on a commercial basis could be seen as meeting an understandable public 
interest and providing information that has at least some replicated scientific evidence to justify the 
activity.  Nevertheless, the predictive value of such tests in the context of training responses or talent 
identification in sport is virtually zero (Pitsiladis et al. 2013) at this time. 
 
There is limited information that can be gleaned from discrete, single marker genetic tests at common 
polymorphisms, beyond an ‘interest’ at an individual level.  So the 46% of companies that present 
information regarding which genetic tests they conduct for their DTC genetic testing, and which test 
only a single variant, should not claim to provide information on which personal exercise training or 
sport decisions can reasonably be made.  The level of qualification and explanation given alongside 
the raw genetic information to individuals appears to vary considerably, as pointed out previously 
(Wagner and Royal 2012).  Some companies appear to treat the genetic information in a suitably 
cautious manner and are suitably careful not to extend preliminary scientific findings into claims that 
extend beyond the published scientific literature base.  However, that sensible approach is not 
universally adopted, and thus some of the claims (overt, or implied) for the extent of the usefulness of 
the single genetic marker information are certainly not supported by sufficiently strong scientific 
evidence.  There is thus a danger that some individuals might make decisions about their personal 
exercise and sport participation on the basis of DTC genetic test information that are not warranted.  It 
is therefore understandable to some extent why more than half (54%) of the companies we identified 
as offering defined DTC genetic tests assess a panel of multiple genetic variants.  One of those seven 
companies apparently tests two variants (ACTN3 and ACE) and six of those seven companies appear 
to test 3-21 variants.  However, as one considers genetic variants beyond those in the ACTN3 and 
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ACE genes that are reasonably well-studied, the level of scientific evidence to support the choice of 
any particular polymorphism reduces considerably in volume, and we suggest the scientific evidence 
is considered weak by the majority of sport and exercise genetics researchers (Bouchard 2011; Eynon 
et al. 2013; Pitsiladis et al. 2013), including ourselves. While commercial pressures undoubtedly exist, 
it would be wise, and more responsible, to wait for a greater scientific consensus before offering tests 
that currently have only weak supporting evidence.  Counselling that puts the genetic information - 
including the limitations of its usefulness - into proper context is recommended as a minimum, 
although it should be remembered that not even a sophisticated counselling service can resolve 
scientific controversy. 
 
It is particularly disappointing that 41% of the companies offering DTC genetic tests related to 
exercise and sport do not publicly state which genetic variants they assess – unless we inadvertently 
failed to navigate our way to such information on the relevant parts of the websites, which is unlikely.  
Again, while commercial pressures undoubtedly exist, it is impossible for anyone - academic scholar 
or otherwise - to scrutinise the service provided by the companies if the detail is not presented to the 
public.  Yet the detail is absolutely crucial, because quite literally millions of genetic tests could 
theoretically be conducted and the choice of which variants are indeed tested - and how the results are 
interpreted - is absolutely fundamental to the usefulness of the test.  The reasons for such apparent 
secrecy are presumably commercial sensitivity in part, although we wonder if failing to publicise the 
tests conducted is a tacit admission that the scientific evidence supporting the genetic variants chosen 
is weak.  Perhaps the specific genetic variants tested by a particular company will change over time as 
scientific knowledge in this field progresses, but if that happens then it rather questions the validity of 
the original test or panel of tests. 
 
In broad terms, based on the published scientific evidence (which is the only criterion that should 
matter), the information provided by these tests may be of interest to many people and may help 
individuals (or sports coaches, etc.) attempt to ‘better understand’ their observed physical limitations 
to performance or training adaptations.  However, there is currently little evidence (there is a notable 
lack of replication, especially (Hughes et al. 2011)) that these kinds of tests provide information 
regarding either predisposition for a particular sport, or prediction of the training response likely to 
occur to a particular training programme, that are useful in a practical sense.  For example, a thorough 
multidisciplinary analysis of the efficacy of these tests in talent identification needs to be conducted.  
It is unknown at this time whether the information provided by genetic testing provides information 
that is not already captured within other, traditional non-genetic tests of physiological, anthropometric 
and performance characteristics that are already routinely used in talent identification. 
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In conclusion, we have little doubt that the future of sports science will become increasingly focused 
on genomics, epigenetics and gene doping as the relevant molecular technologies become faster, 
cheaper and more widely available (Lander 2011).  Recently, 21 SNPs were identified that appear to 
capture the heritable component (approximately 50% of total interindividual variability) of the 
responsiveness to endurance training of the maximal rate of oxygen uptake phenotype (Bouchard et 
al. 2011).  While this observation needs replication, the applications of this kind of insight into an 
individual’s potential to respond to training are clear.  Consequently, sports scientists and medical 
practitioners involved in sport need to ensure they are sufficiently familiar with genomic science to 
capitalize on such findings in an ethically acceptable manner. Companies offering DTC genetic tests 
related to sport and exercise should also ensure that they are responsible in their activities. 
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